These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 35023119)

  • 1. Advanced Health Technologies and Nanotechnologies in Neurodegenerative Diseases.
    Naziris N; Demetzos C
    Adv Exp Med Biol; 2021; 1339():317. PubMed ID: 35023119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Regulatory Landscape of New Health Technologies and Nanotechnologies: The Role of Complexity of Nanosystems.
    Naziris N; Demetzos C
    Adv Exp Med Biol; 2023; 1425():575-589. PubMed ID: 37581831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanomedicines and nanocarriers in clinical trials: surfing through regulatory requirements and physico-chemical critical quality attributes.
    Dri DA; Rinaldi F; Carafa M; Marianecci C
    Drug Deliv Transl Res; 2023 Mar; 13(3):757-769. PubMed ID: 36450964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanotechnology-empowered therapeutics targeting neurodegenerative diseases.
    Wang Z; Gonzalez KM; Cordova LE; Lu J
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2023; 15(5):e1907. PubMed ID: 37248794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanomedicines: addressing the scientific and regulatory gap.
    Tinkle S; McNeil SE; Mühlebach S; Bawa R; Borchard G; Barenholz YC; Tamarkin L; Desai N
    Ann N Y Acad Sci; 2014 Apr; 1313():35-56. PubMed ID: 24673240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methodological needs in the quality and safety characterisation of nanotechnology-based health products: Priorities for method development and standardisation.
    Halamoda-Kenzaoui B; Vandebriel RJ; Howarth A; Siccardi M; David CAW; Liptrott NJ; Santin M; Borgos SE; Bremer-Hoffmann S; Caputo F
    J Control Release; 2021 Aug; 336():192-206. PubMed ID: 34126169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanotechnology: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2006; 6(19):1-43. PubMed ID: 23074489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanomedicines and Nanosimilars: Looking for a New and Dynamic Regulatory "Astrolabe" Inspired System.
    Demetzos C; Kavatzikidou P; Pippa N; Stratakis E
    AAPS PharmSciTech; 2020 Jan; 21(2):65. PubMed ID: 31933006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanosimilars: A Scientific or A Regulatory Debate?
    Demetzos C
    AAPS J; 2024 Jul; 26(4):74. PubMed ID: 38955936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanotechnology and antioxidant therapy: an emerging approach for neurodegenerative diseases.
    Fernandes C; Oliveira C; Benfeito S; Soares P; Garrido J; Borges F
    Curr Med Chem; 2014; 21(38):4311-27. PubMed ID: 25245378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanomedicines: The magic bullets reaching their target?
    Flühmann B; Ntai I; Borchard G; Simoens S; Mühlebach S
    Eur J Pharm Sci; 2019 Feb; 128():73-80. PubMed ID: 30465818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of Nanomedicines and Nano-Similars: Recent Advances in Regulatory Landscape.
    Paliwal R; Kumar P; Chaurasiya A; Kenwat R; Katke S; Paliwal SR
    Curr Pharm Des; 2022; 28(2):165-177. PubMed ID: 34781869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Feeding Next-Generation Nanomedicines to Europe: Regulatory and Quality Challenges.
    Musazzi UM; Franzè S; Condorelli F; Minghetti P; Caliceti P
    Adv Healthc Mater; 2023 Dec; 12(30):e2301956. PubMed ID: 37718353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of Proteomic Tools in Modern Nanotechnological Approaches Towards Effective Management of Neurodegenerative Disorders.
    Ali A; Sheikh IA; Mirza Z; Gan SH; Kamal MA; Abuzenadah AM; Damanhouri GA; Ashraf GM
    Curr Drug Metab; 2015; 16(5):376-88. PubMed ID: 25495738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physical-, chemical-, and biological-responsive nanomedicine for cancer therapy.
    Liao J; Jia Y; Wu Y; Shi K; Yang D; Li P; Qian Z
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2020 Jan; 12(1):e1581. PubMed ID: 31429208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Macromolecular crowding: chemistry and physics meet biology (Ascona, Switzerland, 10-14 June 2012).
    Foffi G; Pastore A; Piazza F; Temussi PA
    Phys Biol; 2013 Aug; 10(4):040301. PubMed ID: 23912807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanomedicine Approaches for Advanced Diagnosis and Treatment of Atherosclerosis and Related Ischemic Diseases.
    Hu B; Boakye-Yiadom KO; Yu W; Yuan ZW; Ho W; Xu X; Zhang XQ
    Adv Healthc Mater; 2020 Aug; 9(16):e2000336. PubMed ID: 32597562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulatory challenges of nanomedicines and their follow-on versions: A generic or similar approach?
    Mühlebach S
    Adv Drug Deliv Rev; 2018 Jun; 131():122-131. PubMed ID: 29966685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Nanomedicine: application of nanotechnology in medicine. Opportunities in neuropsychiatry].
    Szebeni J
    Neuropsychopharmacol Hung; 2011 Mar; 13(1):15-24. PubMed ID: 21451188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Nanomedicine as a part of nanotechnology].
    Piotrovskiĭ LB
    Vestn Ross Akad Med Nauk; 2010; (3):41-6. PubMed ID: 20420215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.